Research & Development
Genmab reports net sales of USD765m of DARZALEX in Q3 2019
16 October 2019 -

Genmab A/S (CPH:GMAB), a biotechnology company specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer, reported on Tuesday that worldwide net sales of DARZALEX (daratumumab), as reported by Johnson & Johnson, were USD765m in the third quarter of 2019. Out of this, net sales were USD402m in the US and USD363m in the rest of the world.

The company said it receives royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech Inc to develop, manufacture and commercialize DARZALEX.

DARZALEX is reportedly the first monoclonal antibody (mAb) to receive US Food and Drug Administration (US FDA) approval to treat multiple myeloma.

Daratumumab is being developed by Janssen Biotech Inc under an exclusive worldwide license to develop, manufacture and commercialise daratumumab from Genmab. A comprehensive clinical development programme for daratumumab is ongoing, including multiple phase III studies in smouldering, relapsed and refractory and frontline multiple myeloma settings.

Also, additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis, NKT-cell lymphoma and B-cell and T-cell ALL.

In addition, Daratumumab has received two Breakthrough Therapy Designations from the US FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.

Login
Username:

Password: